New Tests

Get Started with NeoGenomics

Catch up with new and enhanced tests in all methodologies

Innovation is one of NeoGenomics’ company values. We mean that literally – innovation is one of our Core Values – and we take it personally. In 2016, we launched 50 new or enhanced tests. In 2017, we continue to innovative by launching new tests n hereditary and somatic molecular genetics, IHC, FISH, flow cytometry, and cytogenetics to keep our test menu at the forefront of cancer diagnostics. To stay up-to-date with our latest news, please sign up for our newsletter here.

Please review our list of recently launched tests.

• Universal Fusion/Expression Profile (new 3-29-17)
• PD-L1 SP142 FDA IHC for TECENTRIQ™ in lung cancer (new)
• Hereditary Cancer Susceptibility for Pediatrics (new 12-22-16)
• Hereditary DNA Repair Panel for Prostate Cancer (new 12-12-16)
• CXCL13 IHC (new 12-5-16)
• Glutamine Synthetase IHC (new 12-5-16)
• BAP1 IHC (new 12-5-16)
• INI1 IHC (new 11-28-16)
• NRAS Exon 4 Mutation Analysis (new 11-21-16)
• NeoTYPE™ AITL/Peripheral T-Cell Lymphoma Profile (new 11-14-16)
• RHOA Mutation Analysis (new 11-14-16)
• HSD3B1 Genotyping (new 11-14-16)
• NeoLAB™ EGFR T790M Liquid Biopsy (new 11-07-16)